JNJ Johnson & Johnson
FY2025 10-K
Johnson & Johnson (JNJ) filed its fiscal year 2025 10-K annual report with the SEC on Feb 11, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model not detailed; filing focuses on corporate governance and compliance policies
- • New emphasis on transparency with online posting of Code of Business Conduct amendments and waivers within five business days
Management Discussion & Analysis
- • Revenue $94.2B in 2025, up 6.0% YoY from $88.8B in 2024; U.S. sales $53.8B (+6.9%), international $40.4B (+5.0%)
- • Operating margin 34.6% in 2025 vs 18.8% in 2024; Innovative Medicine margin 36.9% vs 33.2%; MedTech margin 12.2% vs 11.7%
Risk Factors
- • Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws
- • CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry
Financial SummaryXBRL
Revenue
$94.2B
Net Income
$26.8B
Gross Margin
67.9%
Net Margin
28.5%
ROE
32.9%
Total Assets
$199.2B
EPS (Diluted)
$11.03
Operating Cash Flow
$24.5B
Source: XBRL data from Johnson & Johnson FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Johnson & Johnson
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.